granisetron 2mg tablets
apc pharmaceuticals & chemicals (europe) ltd - granisetron hydrochloride - oral tablet - 2mg
granisetron 2mg tablets
alliance healthcare (distribution) ltd - granisetron hydrochloride - oral tablet - 2mg
granisetron 2mg tablets
sigma pharmaceuticals plc - granisetron hydrochloride - oral tablet - 2mg
granisetron 2mg tablets
cubic pharmaceuticals ltd - granisetron hydrochloride - oral tablet - 2mg
granisetron 2mg tablets
colorama pharmaceuticals ltd - granisetron hydrochloride - oral tablet - 2mg
granisetron 2mg tablets
ennogen healthcare ltd - granisetron hydrochloride - oral tablet - 2mg
granisetron 2mg tablets
j m mcgill ltd - granisetron hydrochloride - oral tablet - 2mg
granisetron 1mg tablets
apc pharmaceuticals & chemicals (europe) ltd - granisetron hydrochloride - oral tablet - 1mg
granisetron 1mg tablets
torrent pharma (uk) ltd - granisetron hydrochloride - oral tablet - 1mg
granisetron hydrochloride tablet, film coated
orchidpharma inc - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg - granisetron hydrochloride tablets are indicated for the prevention of: - nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.